Mounjaro import rule lets Koreans carry cheaper Japanese prescriptions home
Since November 12, Korean travelers may bring home up to 12 weekly doses of Mounjaro prescribed and bought abroad. A month of the starting dose costs about 278,000 won in Korea and 7,000 yen at one Tokyo clinic.
Who feels it
-
Patients
Rethink
A legal way to use cheaper Japanese prescriptions, but only for your own supply and within the dose limit.
-
Sellers
Adjust
Buying for others or reselling stays illegal; reports expect informal resellers to try anyway.
-
Prescribers
Worth knowing
Korean doctors may see patients started abroad after short remote visits, with little follow up.
-
Pharmacies
Worth knowing
Korean cash sales of Mounjaro may fall if travel for cheaper supply grows.
-
Payers
Worth knowing
No direct cost to Korean public insurance, which does not reimburse Mounjaro, but outcome tracking gets harder.
South Korea's new Mounjaro import rule took effect on November 12, letting travelers bring home weight loss drugs prescribed and bought abroad for their own treatment. The change opened a legal route to Japan, where a month of the starting dose can cost about a quarter of the Korean price, and Japanese clinic appointments filled within a day.
What the Mounjaro import rule changes
The Ministry of Food and Drug Safety announced the revision on November 11 after talks with the Korea Customs Service, and it applied from the next day, the Korea JoongAng Daily reported. Before the change, customs officers had used the ministry's list of flagged medicines against individual travelers, so even Mounjaro prescribed in the traveler's own name could be stopped at the border. Under the new terms a traveler may carry up to six bottles of a medicine approved by the overseas regulator and bought on a doctor's prescription. Larger amounts are allowed up to a three month supply based on the prescribed dose. For once weekly injections such as Mounjaro, the cap is 12 doses.
The rule is not limited to one brand. It covers Mounjaro and Wegovy, and it also applies to Koreans taking medicines prescribed at home on trips abroad, to international students and to foreign tourists who carry overseas prescriptions into Korea. The ministry moved after the JoongAng Ilbo reported on October 26 that travelers with valid prescriptions were having the drugs held at customs. The change does not create any new approval or subsidy. It simply stops customs from treating a personal, prescribed supply as an illegal import. A traveler still needs a genuine prescription, a medicine approved by the country where it was bought, and an amount within the limits, or the old rules apply.
Why the price gap drives demand
The money explains the rush. A four week supply of the Mounjaro starting dose costs about 278,000 won, roughly $208, in Korea according to a pharmacy price map cited by the newspaper, while one Tokyo clinic charges 7,000 yen, about $44, for the same supply. Over the three months that the Mounjaro import rule allows, that is 834,000 won in Korea against about 21,000 yen in Japan, a gap the paper put at about 79 percent. Earlier reporting gave a wider Korean range of 280,000 to 350,000 won a month. In Korea, Mounjaro is not covered by national health insurance even for people with diabetes, so the full price falls on the patient.
Over the three months that the Mounjaro import rule allows, that is 834,000 won in Korea against about 21,000 yen in Japan, a gap the paper put at about 79 percent.
Japan's price is low because the government sets it. Tirzepatide is covered by Japanese national health insurance as Mounjaro for type 2 diabetes and as Zepbound for obesity, with official prices fixed by the state. Patients paying privately still pay the full amount, but those official prices anchor what clinics charge, and competition between clinics has pushed prices lower. "Japan lowered drug prices through government led measures," said Dr Oh Sang-woo of Dongguk University Ilsan Hospital, who argued that Korea should negotiate with drug makers for lower prices. Dr Cho Young-min of Seoul National University Hospital said the burden should be eased for patients who need treatment.
| Item | Korea | Japan |
|---|---|---|
| Four weeks of the starting dose | About 278,000 won | About 7,000 yen at one Tokyo clinic |
| Three month supply | 834,000 won | About 21,000 yen |
| Public insurance | Not covered, even for diabetes | Covered with state set prices |
| Import limit for travelers | 12 weekly doses from November 12, 2026 | Not applicable |
Clinics fill up and resellers may follow
Demand showed up at once. A Japanese telemedicine platform serving Korean travelers had no appointments left on November 12, the first day of the new rule, with all 384 slots booked through November 19, the JoongAng Daily reported. Travel agencies began advertising trips built around the clinic visits, and one agency head told the paper that agencies have waiting lists running into the hundreds. Japanese clinics have also started reaching Korean patients through Korean language websites and social media. Industry sources quoted by the paper expect buy on behalf services and informal cross border resellers to appear, which would fall outside the personal use rule entirely.
That last point is where access turns into risk. The rule covers a traveler's own prescribed supply, not medicines bought for someone else or resold at home, and those activities remain illegal imports. Injectable pens also need cold storage, so a long trip home without proper handling can damage the drug. Doctors in Korea may face patients who started treatment after a short remote consultation abroad, with little follow up for side effects. Readers who want the wider picture of how patients pay for these drugs outside insurance can see our guide to access pathways outside insurance. The safest route remains a prescription from a doctor who can monitor treatment.
What it means for prices in Korea
The cross border trade puts pressure on Korean list prices without changing them. Lilly has not commented on the rule in the reports, and no Korean price cut has been announced. Local competition is starting to appear, as we reported when Hanmi priced its Eppe obesity drug at close to half the price of Mounjaro. Doctors quoted by the JoongAng Daily want prices negotiated down or the burden on patients eased, but there is no sign yet of either step. For now, the cheapest legal option for many Korean patients is to see a doctor in Japan and carry the medicine home.
Insurers and the national health system face a separate question. Because Mounjaro is not reimbursed in Korea, the cost of Japanese treatment falls on patients rather than on the public budget, and the Korean system loses little directly. But a large flow of patients treated abroad could make it harder to track side effects and outcomes, and it highlights how much Korean patients pay compared with their neighbours. Pharmacies in Korea may see fewer cash sales of Mounjaro if the trend grows. The ministry has not said whether it will review the limits after the first weeks, or how customs will check that a supply is truly for personal use.
Conclusion
The Mounjaro import rule gives Korean patients a legal way to use cheaper Japanese prescriptions, within a 12 dose limit. It does not lower Korean prices or add insurance cover, and resale stays illegal. Whether Seoul answers the price gap with negotiation or coverage is still open.
Source Korea JoongAng Daily, November 11 and 12, 2026, on the Ministry of Food and Drug Safety revision
Sources
Spotted an error? Tell us through the contact form; we follow the corrections policy.